Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine and T-reg Depleted Lymphocytes in Melanoma
NCT00303836Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2005
- Primary completion
- Jan 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp100 antigen and mart-1 antigen in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective clinical response (CR or PR) up to 2 years. Started Nov 2005; status: terminated.
02
Drugs
gp100 antigenmart-1 antigen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00303836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303836.